ArticleOncotarget2016

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.

Chu-Ying Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.